Top Page
Shield Therapeutics
(LSE:STX)
Shield Therapeutics (STX) vs. iShares MSCI United Kingdom ETF (EWC)
Shield Therapeutics Business Overview & Revenue Model
Shield Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.07M | 25.18M | 13.09M | 5.50M | 1.52M | 10.39M |
| Gross Profit | 14.32M | 10.57M | 4.03M | 2.00M | 539.00K | 9.03M |
| EBITDA | -9.93M | -16.58M | -30.29M | -46.07M | -17.69M | 820.00K |
| Net Income | -16.42M | -21.27M | -33.29M | -40.44M | -19.34M | -2.63M |
Balance Sheet | ||||||
| Total Assets | 62.10M | 45.90M | 48.80M | 22.07M | 44.41M | 32.53M |
| Cash, Cash Equivalents and Short-Term Investments | 10.81M | 5.61M | 13.95M | 2.82M | 12.12M | 2.94M |
| Total Debt | 27.05M | 21.06M | 20.41M | 6.10M | 156.00K | 28.00K |
| Total Liabilities | 76.96M | 46.95M | 26.49M | 16.65M | 3.38M | 2.25M |
| Stockholders Equity | -14.86M | -1.05M | 11.79M | 5.43M | 40.69M | 30.28M |
Cash Flow | ||||||
| Free Cash Flow | -8.15M | -7.03M | -40.07M | -20.14M | -18.80M | -1.42M |
| Operating Cash Flow | -8.15M | -7.01M | -37.13M | -18.25M | -16.74M | -1.40M |
| Investing Cash Flow | -1.30M | -1.89M | -2.43M | -1.70M | -2.05M | -20.00K |
| Financing Cash Flow | 11.83M | 4.21M | 49.66M | 7.71M | 27.58M | -47.00K |
Shield Therapeutics Technical Analysis
Shield Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £3.47B | 12.15 | 15.66% | 4.16% | 3.73% | 27.13% | |
65 Neutral | £84.57M | ― | ― | ― | ― | ― | |
63 Neutral | £111.49M | -5.65 | -396.71% | ― | 93.48% | 51.18% | |
57 Neutral | £730.83M | -14.17 | ― | ― | -0.28% | 22.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Shield Therapeutics Corporate Events
Shield Therapeutics has confirmed that its issued share capital comprises 1,067,828,251 ordinary shares, each carrying equal voting rights and with no shares held in treasury, establishing the official share count that investors must use when calculating notifiable holdings under UK disclosure and transparency rules. The clarification of total voting rights provides greater transparency for shareholders and regulators, supporting accurate reporting of significant stakes in the company as it continues to commercialise its flagship iron deficiency treatment ACCRUFeR/FeRACCRU globally.
The most recent analyst rating on (GB:STX) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Shield Therapeutics has secured U.S. Food and Drug Administration approval to extend the indication for its oral iron therapy ACCRUFeR (ferric maltol) to include pediatric patients aged 10 years and older, following a priority review supported by positive Phase 3 pediatric trial data. The company plans to seek a further indication expansion to cover children from 1 month of age using a new ferric maltol suspension formulation, which could also benefit adults unable to swallow capsules, strengthening ACCRUFeR’s clinical reach and reinforcing Shield’s position in the growing iron deficiency market.
The most recent analyst rating on (GB:STX) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Shield Therapeutics has applied for a block listing of 15,000,000 ordinary shares to the London Stock Exchange, which will be allocated to the company’s Retention and Performance Share Plan and admitted to trading on 23 December 2025. The application aligns with the company’s focus on iron deficiency treatments, notably ACCRUFeR®, positioning Shield Therapeutics as a leader in this $2.3 billion market, while enhancing operational flexibility and rewarding key personnel to support further growth.
The most recent analyst rating on (GB:STX) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Shield Therapeutics has been awarded Gold at the 2025 Titan Brand Awards for the rebranding of its product ACCRUFeR®, highlighting its effective brand strategy and communication in the competitive pharmaceutical market. This recognition underscores ACCRUFeR®’s position as a leading brand in the iron deficiency market, where it serves a significant unmet medical need, and marks the beginning of Shield’s digital marketing initiative aimed at further growth.
The most recent analyst rating on (GB:STX) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Shield Therapeutics has amended its senior secured debt financing, enhancing its financial position by increasing available funds to $50 million, with $15 million earmarked for future mergers and acquisitions. The revised terms, achieved through collaboration with SWK Holdings and Runway Growth Finance, lower debt costs and extend the interest-only period, providing Shield with greater flexibility to pursue growth opportunities and strengthen its market position in the pharmaceutical industry.
The most recent analyst rating on (GB:STX) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Shield Therapeutics announced the initiation of a Phase II clinical trial in Japan for ACCRUFeR® (ferric maltol) as a treatment for Pulmonary Arterial Hypertension (PAH). This trial, conducted by its partner MEDLEAP Pharma, aims to support a Phase III trial and potential regulatory submissions by 2028. The development is significant as it addresses the challenges of long-term iron supplementation in PAH patients, potentially positioning ACCRUFeR® as a core treatment in this field.
The most recent analyst rating on (GB:STX) stock is a Buy with a £0.10 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Shield Therapeutics announced the presentation of pediatric pharmacokinetic results for ferric maltol at the upcoming American Society of Hematology Conference. The study confirmed the suitability of ferric maltol for iron replacement in children, supporting its potential expansion to younger populations and highlighting its importance in addressing unmet medical needs in pediatric iron deficiency treatment.
The most recent analyst rating on (GB:STX) stock is a Buy with a £0.10 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Shield Therapeutics has announced that its product, ACCRUFeR®, has received marketing authorization from the Korean Ministry of Food and Drug Safety for treating iron deficiency in adults. This approval, following a successful pharmacokinetic study and new drug application by Korea Pharma, signifies a major advancement in expanding ACCRUFeR®’s availability in South Korea. Shield is set to receive payments and royalties from sales in the region, reinforcing its commitment to global patient access and highlighting the strength of its international partnerships.
The most recent analyst rating on (GB:STX) stock is a Buy with a £0.10 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Shield Therapeutics reported its strongest quarterly performance to date, with a 15% increase in ACCRUFeR® prescriptions over the previous quarter, achieving net revenues of $13.1 million. The company remains on track to become cash flow positive by the end of 2025, driven by strategic marketing initiatives and strong sales efforts, marking a significant milestone in its operational progress.
The most recent analyst rating on (GB:STX) stock is a Buy with a £0.10 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Shield Therapeutics announced the grant of share options to its CEO, Anders Lundstrom, as part of the company’s Retention and Performance Share Plan. This move is part of Lundstrom’s annual equity grant, with options granted over 1,547,262 ordinary shares. The grant reflects Shield’s commitment to retaining key leadership as it continues to focus on its market-leading product, ACCRUFeR®, which addresses a significant unmet need in iron deficiency treatment. The company’s strategic positioning in the pharmaceutical industry is reinforced by its global licensing agreements and the growing market opportunity for its flagship product.
The most recent analyst rating on (GB:STX) stock is a Buy with a £0.10 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.